In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Eyes Full, $50 billion Alcon Takeover

Executive Summary

Novartis on Jan 4 announced it was exercising its option to purchase Nestlé's remaining 52 percent stake in eye-care group Alcon for $28.1 billion. The Swiss Big Pharma will finish up paying almost $50 billion for full control of the group, given its controversial attempt to buy out the minority Alcon shareholders for a further $11.2 billion.
Advertisement

Related Content

Biopharma Quarterly Statistics Q1 2010
Sanofi Builds US-based Consumer Powerhouse in Preparation for Allegra OTC Switch
Bristol Spins Off Mead Johnson in Stock Swap, Finally Pure Biopharma
Bristol Spins Off Mead Johnson in Stock Swap, Finally Pure Biopharma
Sanofi Creates Ophtho Division through Earn-Out Acquisition of Fovea
Venture Eyes Ophthalmology--And Likes What It Sees
Pharma's Strategic Divide: Focus or Diversify
Pharma's Strategic Divide: Focus or Diversify
Novartis' New Kind of Pharma Deal
Novartis' New Kind of Pharma Deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel